What Makes Teva Pharmaceuticals (TEVA) a Successful Brand?

Greenlight Capital, an investment management company, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Greenlight Capital’s investment strategy focuses on constructing a bottom-up portfolio comprising undervalued long positions and overvalued short positions, while also including a macro book to hedge risks and capture insights. The Partnership returned 9.0% (net) in 2025 compared to 17.9% for the S&P 500 index. In contrast, it returned 8.5% in Q4, compared to 2.7% for the index. The Partnership has returned $6.1 billion, net of fees and expenses, to its investors since its inception in May 1996.  For more information on the Partnership’s top picks in 2025, please check its top five holdings.

In its fourth-quarter 2025 investor letter, Greenlight Capital highlighted stocks like Teva Pharmaceutical Industries Limited (NYSE:TEVA).  Teva Pharmaceutical Industries Limited (NYSE:TEVA) is an Israel-based pharmaceutical company. Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares traded between $12.47 and $33.42 over the past 52 weeks. On January 28, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) stock closed at $33.21 per share. One-month return of Teva Pharmaceutical Industries Limited (NYSE:TEVA) was 7.08%, and its shares gained 66.85% of their value over the last three months. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has a market capitalization of $36.63 billion.

Greenlight Capital stated the following regarding Teva Pharmaceutical Industries Limited (NYSE:TEVA) in its fourth quarter 2025 investor letter:

"Teva Pharmaceutical Industries Limited (NYSE:TEVA): The company continued to deliver rapid growth in its patented branded portfolio, with results consistently exceeding expectations. The market began to reflect this progress only after policy headwinds eased, including a negotiated pricing agreement with the Centers for Medicare & Medicaid Services for TEVA’s drug Austedo beginning in 2027. These developments more than offset muted performance in the generics business and highlight the progress TEVA has made in its transition to a branded pharmaceutical company."

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 60 hedge fund portfolios held Teva Pharmaceutical Industries Limited (NYSE:TEVA) at the end of the third quarter, up from 57 in the previous quarter. While we acknowledge the potential of Teva Pharmaceutical Industries Limited (NYSE:TEVA) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Teva Pharmaceutical Industries Limited (NYSE:TEVA) and shared the list of best performing pharma stocks in 2025. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.